Vaccines Won’t Be Enough17 Aug 2021 14:05
On Monday, analysts at Jefferies wrote that the continued emergence of new Covid-19 variants demonstrates that vaccines won’t be enough to fight the virus. Few treatments have been developed so far, and among those, few are particularly effective. The analysts say that a substantial commercial opportunity remains for the company that develops a good Covid-19 therapeutic.
“Despite their relative lack of efficacy and lack of convenience, the small number of approved and authorized products still managed to achieve collective 1QCY21 sales of more than $3bn,” the analysts wrote. “An effective and convenient treatment could potentially achieve peak annual sales in excess of $10bn.”
The note highlights a long list of companies that are working on Covid-19 therapeutics as potential investment opportunities. “An orally available broad-spectrum antiviral, suited for immediate administration to newly diagnosed cases, would be ideal,” the analysts write. “With new Cov19 diagnoses are currently running in excess of 500,000 per day, such a drug would likely have huge commercial potential.”
https://www.barrons.com/articles/covid-cases-vaccines-therapeutics-variants-51629117705